14/05/2026
For many years, the term Polycystic Ovarian Syndrome (PCOS) has failed to fully reflect the complexity of this condition. Despite its name, most patients diagnosed with PCOS do not actually have ovarian cysts, and the condition extends far beyond reproductive health alone.
Following more than a decade of international collaboration involving clinicians, researchers, and patients, PCOS has now officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change acknowledges what healthcare professionals and patients have long understood: this is a complex endocrine and metabolic condition that can affect hormonal health, insulin regulation, fertility, cardiovascular risk, mental health, skin, and overall well being.
The renaming process was informed by extensive global consultation and supported by organisations with the aim of improving understanding, reducing stigma and confusion, and encouraging earlier diagnosis and more comprehensive care.
Importantly, this is more than a change in terminology. It represents a shift toward recognising the full-body impact of the condition and validating the experiences of millions of women who have often felt misunderstood or dismissed because of the limitations of the previous name.
As women’s health professionals, we hope this updated terminology helps patients feel more informed, empowered, and better supported throughout their healthcare journey.